TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01574898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - A mg
Description: Single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - B mg
Description: Single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0474 - C mg
Description: Single oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: V0018 - B mg
Description: Single oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niquitin® Fresh Mint 4 mg
Description: Single oral administration
Study: NCT04979897

Intervention type: OTHER
Intervention: Intensive care unit stay during the COVID-19 pandemic
Description: Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study

Intervention type: OTHER
Intervention: Intensive care unit stay during the COVID-19 pandemic
Description: Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
Study: NCT02306291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: induction chemotherapy
Study: NCT00805649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low fluorescence Photodynamic therapy
Description: 42 J/cm2 for 72 sec

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core pars plana vitrectomy
Description: 24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: intravitreal injection of 0.8 mg dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal injection of 1.25 mg bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal injection of 1.25 mg bevacizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core pars plana vitrectomy
Description: 0.4 mL core pars plana vitrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcincolone
Description: intravitreal injection of 8 mg triamcincolone
Study: NCT01930487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement with antioxidants
Description: Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement with antioxidants
Description: Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
Study: NCT01833793

Intervention type: DRUG
Intervention: Levonorgestrel IUD (Mirena, BAY86-5028)
Description: Women who have been prescribed Mirena in contraception; followed up for 12 months
Study: NCT05488028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezo-electric surgery of impacted lower third molars
Description: During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotary bur surgery of impacted lower third molars
Description: During lower third molar surgery, osteotomy is performed using rotary instruments
Study: NCT02366715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeatedHumidifiedHighFlowNasalCannula
Description: We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016.
Study: NCT02020213

Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: 400 mg po bid for 8 weeks
Study: NCT04999319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB
Description: Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
Study: NCT04360291

Intervention type: OTHER
Intervention: Eye tracker
Description: In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded

Intervention type: OTHER
Intervention: Eye tracker
Description: In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
Study: NCT00779181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a high total daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a mid level total daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX415
Description: ADX415 taken three times a day to achieve a low total daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken three times a day
Study: NCT03796923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early follow-up visit after discharge
Description: Early follow-up visit and different degrees of specialized care after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early follow-up visit after discharge
Description: Early follow-up visit and different degrees of specialized care after discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive geriatric assessment (CGA)
Description: Comprehensive geriatric assessment (CGA) during admission

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Description: Comprehensive geriatric assessment (CGA) during admission
Study: NCT01957735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP31510 monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BP31510 in combination with chemotherapy
Study: NCT00954668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate angiography and revascularization
Description: immediate angiography \< 2 hours after randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early invasive angiography
Description: early invasive angiography 12-72 h after randomization
Study: NCT00348907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: late thermal cure
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
Study: NCT03796923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continued geriatric care
Description: Continued specialized geriatric care after discharge

Intervention type: OTHER
Group type: OTHER
Intervention: Possible follow-up visit from GP
Description: Usual care: follow up visit from GP within one week after discharge
Study: NCT01177826

Intervention type: PROCEDURE
Intervention: Sample collection
Description: Stool sample

Intervention type: PROCEDURE
Intervention: Sample collection
Description: Stool sample
Study: NCT01992900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim dispersible oral tablet
Description: The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eurartesim film coated tablet
Description: The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
Study: NCT02569645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
Study: NCT02920034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency denervation of the main renal arteries
Description: Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation of renal arteries and branches
Description: Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
Study: NCT02591511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart phone and pad
Description: Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stroke-related health education manual
Description: stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
Study: NCT03254849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Description: 1 tablet
Study: NCT06118190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: All participants treated with procaine and lidocaine injection for treatment.
Study: NCT01392391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task Oriented Exercise Training
Description: Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Care Get with the Guidelines
Description: Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica
Study: NCT02449915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
Study: NCT02804685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise protocol
Description: The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
Study: NCT03307213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ CoCr Biolimus A9™ stent
Description: Stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioFreedom™ SS Biolimus A9™ stent
Description: Stent implantation
Study: NCT02920034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound denervation of the main renal arteries
Description: Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
Study: NCT03884803

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-health website
Description: Access to the e-health intervention (website)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Control group to continue with standard care
Study: NCT01949792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa (activated)
Description: Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa (activated)
Description: Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
Study: NCT03781154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
Study: NCT06227416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: punch biopsy (2-4 mm) depending on the size of the AK lesion.
Study: NCT03303625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF (1*10^11 vp)
Description: Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF (5*10^10 vp)
Description: RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
Study: NCT02263742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer whole health intervention
Description: Provide wraparound peer support, education, and navigation to individuals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EBPs at Wellness Center
Description: four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
Study: NCT05376241

Intervention type: BEHAVIORAL
Intervention: Decision aid
Description: Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
Study: NCT00273806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for 4 behavioral risks by medical assistants.
Study: NCT01169415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: Participants will receive a protracted (30 days) course of dexamethasone after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive a protracted (14 days) course of dexamethasone after surgery.
Study: NCT00882596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
Study: NCT01926418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning tasks
Description: Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning tasks
Description: Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning.
Study: NCT03868618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio™ system
Description: The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
Study: NCT04542824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab (monotherapy)
Description: Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
Study: NCT00296478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin
Description: Endometrin 100mg TID x 10weeks
Study: NCT03274076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral medication tofacitinib 5 mg twice a day for 24 weeks.
Study: NCT00296478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone
Description: Crinone QD x 10weeks
Study: NCT03274076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral Placebo 5 mg twice a day for 24 weeks
Study: NCT03879538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Study: NCT02553889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 416858
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 416858
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 416858
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT05208034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
Study: NCT01530334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg
Description: Gefitinib 250mg once daily
Study: NCT04542824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epcoritamab
Description: Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Description: 21-day cycles